BioGaia AB, a Swedish pharmaceutical company, has a low-risk ESG score of 15.7. Specializing in probiotic products, the company focuses on healthcare development and marketing. With operating segments in Paediatrics, Adult Health, and Other, BioGaia offers a variety of products such as gut health tablets, oral rehydration solutions, and cultures used in licensee products. Geographically, BioGaia operates in Asia Pacific, Europe, the Middle East, Africa, and the Americas.